CURRICULUM VITAE
Prof essor STEVEN J. HARPER MB Ch B (Hons), MD, B.Sc. (Hons), FRCP(UK).
1. PERSONAL INFORMATION
Name: Steven James HARPER.
DoB: 19th September 1959
GMC No 2855075
2. PRESENT Consultant Nephrologist, Southmead Hospital, Bristol. 1996-present. Clinical Dorector Microvascular
Research Laboratories, Dept Physiology/Pharmacology, University of Bristol.
3. PREVIOUS APPOINTMENTS
Senior Registrar in Nephrology, Leicester General Hospital (LGH)
1st Mar 1996 - 31st Aug 1996
Wellcome Trust Medical Graduate Advanced Training Fellow(034937/91).
1st Mar 1993 - 29th Feb 1996
Hon SR Nephrology AMRC No 022, LGH
Registrar General Medicine & Nephrology, LGH
17th Dec1991 -28th Feb 1993
Research Registrar in Nephrology, LGH
1st Aug 1989 - 16th Dec1991
Registrar Gen Med & Nephrology, University Dept.of Med, Royal
25th Sep1988 - 31st Jul 1989
Hallamshire, Hospital, Sheffield.
Senior House Officer, Manchester Royal Infirmary
1st Dec 1986 - 24th Sep 1988
Senior House Officer, North Manchester General Hospital
1st Aug 1986 - 31st Nov1986
SHO, Regional Cardiothoracic Centre,Wythenshawe Hosp, Manchester
1st Aug 1985 - 31st Jul 1986
House Physician, Bradford Royal Infirmary.
1st Feb 1985 - 31st July 1985
House Surgeon, University Hospital of South Manchester
1st Aug 1984 - 31st Jan 1985
4. ACADEMIC QUALIFICATIONS
2001
FRCP
Royal College of Physicians
1992
M.D.
Manchester University
1987
MRC(UK).
Royal College of Physicians
1984
MB.ChB. (Hons)
Manchester University
1981
BSc. (Hons) – 1st CLASS
Manchester University.
5. SPECIAL AWARDS/HONOURS/DISTINCTIONS
1. 1980 Douglas Prize for Prosection.
University of Manchester
2. 1980 Medical Research Council BSc. Scholarship.
Medical Research Council
3. 1984 Dumville Prize for Surgery.
University of Manchester.
4. 1984 Distinction in Surgery.
University of Manchester.
5. 1991 Postgraduate Clinical Research Prize.
University of Leicester.
6. 1993 Elizabeth Wherry Research Award
British Medical Association
for the treatment of Kidney Disease.
7. 1993 Wellcome Trust Medical Graduate
Wellcome Trust
Advanced Training Fellowship (3 years)
8. 1996 A E G Raine Young Investigator Award.
British Renal Association.
9. 1999 Wellcome Trust research Leave Fellowship (3 years)
Wellcome Trust
10. 2009 Honorary Chair in Physiology & Pharmacology
University of Bristol
Publications (total 86) pertinent selection from 2002
1. Bates DO, Cui T-G, Doughty JM, Winkler M, Sugiono M, Shields J, Peat D, Gillatt D, Harper SJ.
VEGF165b – an inhibitory splice variant of vascular endothelial growth factor is downregulated in renal
cell carcinoma. Cancer Res 2002; 62: 4123-4131.
2. T-G Cui, RR Foster, M Saleem, PW Mathieson, DA Gillatt, DO Bates, Harper SJ . Differentiated human
podocytes endogenously express an inhibitory isoform of vascular endothelial growth factor (VEGF 165b) mRNA
and protein. Am J Physiol – Renal Physiol 2004; 286(4): 767-73.
in isolated intact Wistar Rat glomeruli. J Physiol 2006; 570(Pt 1): 141-156.
3.D.O. Bates, P.P MacMillan, J.G. Manjaly, Y. Qiu, S.J. Hudson, A.J. Hunter, P. Soothill, C. Reid, L.F.
Donaldson, Harper SJ. The endogenous anti-angiogenic family of splice variants of VEGF, VEGFxxxb, are down
regulated in pre-eclamptic placentae at term. Clinical Science 2006; 110(5): 575-85.
4.Perrin RM, Harper SJ, Corrall R, Bates DO. Hyperglycemia stimulates a sustained increase in
hydraulic conductivity in vivo without any change in reflection coefficient. Microcirculation. 2007 SepOct;14(7):683-96.
5.Rennel ES, Waine E, Guan H, Leenders W, Woolard J, Sugiono M, Gillatt D, Kleinerman, Bates DO, Harper
SJ. The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice. Br J
Cancer 2008; 98(7): 1250-7.
6.Rennel ES, Wheatley ER, Schüler Y, Kelly SP, Cebe-Suarez S, Ballmer-Hofer K, Stewart L, Harper SJ, Bates
DO. Pharmacokinetics of the endogenous anti-angiogenic VEGF isoform, VEGF165b in mice are equivalent to
VEGF165. Eur J Cancer 2008; 44(13): 1883-94
7. Qiu Y, Bevan H, Weeraperuma S, Wratting D, Murphy D, Neal CR, Bates DO, Harper SJ. Mammary alveolar
development during lactation is inhibited by the endogenous antiangiogenic growth factor isoform, VEGF 165b.
FASEB J. 2008; 22(4): 1104-12.
8.Kawamura H, Li X, Harper SJ, Bates DO, Claesson-Welsh L. VEGF-A165b is a weak in vitro agonist for VEGF
receptor-2 due to lack of co-receptor binding and deficient regulation of kinase activity. Cancer Research 2008;
68(12): 4683-92.
9. Bevan S, van den Akker, NMS , Qiu Y, Polman, JAE, Foster RR, Yem J, Nishikawa A, Satchell SC, Harper
SJ, Gittenberger de Groot, AC, Bates, DO. The alternatively spliced anti-angiogenic family of VEGF isoforms,
VEGFxxxb, in human kidney development. Nephron Physiol 2008 In Press
10.Harper SJ. Bates DO. VEGF Splicing. The key to anti-angiogenic therapeutics?
Nature Cancer Rev 2008 Nov;8(11):880-7.
11. The anti-angiogenic isoforms of VEGF in health and disease.
Qiu Y, Hoareau-Aveilla C, Oltean S, Harper SJ, Bates DO.
Biochem Soc Trans. 2009 Dec;37(Pt 6):1207-13.
12. Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to antiangiogenic isoforms - a novel therapeutic strategy for angiogenesis.
Nowak DG, Amin EM, Rennel ES, Hoareau-Aveilla C, Gammons M, Damodoran G, Hagiwara M,
Harper SJ, Woolard J, Ladomery MR, Bates DO.
J Biol Chem. 2009 Nov 11. [Epub ahead of print]
13. VEGF(121)b, a new member of the VEGF(xxx)b family of VEGF-A splice isoforms, inhibits
neovascularisation and tumour growth in vivo. Rennel ES, Varey AH, Churchill AJ, Wheatley ER,
Stewart L, Mather S, Bates DO, Harper SJ. Br J Cancer. 2009 Oct 6;101(7):1183-93. Epub 2009 Aug 25.
14. Molecular Diversity of VEGF-A as a Regulator of Its Biological Activity.
Woolard J, Bevan HS, Harper SJ, Bates DO. Microcirculation. 2009 Jun 10:1-21. [Epub ahead of print]
15. Therapeutic potential of manipulating VEGF splice isoforms in oncology.
Rennel ES, Harper SJ, Bates DO. Future Oncol. 2009 Jun;5(5):703-12. Review.
16. New aspects of glomerular filtration barrier structure and function: five layers (at least) not three.
Salmon AH, Neal CR, Harper SJ. Curr Opin Nephrol Hypertens. 2009 May;18(3):197-205. Review.
17. Angiopoietin-1 alters microvascular permeability coefficients in vivo via modification of endothelial
glycocalyx. Salmon AH, Neal CR, Sage LM, Glass CA, Harper SJ, Bates DO.
Cardiovasc Res. 2009 Jul 1;83(1):24-33. Epub 2009 Mar 18
Grant Funding
2008
 BHF Role of VEGF isoforms in the regulation of glomerular microvascular permeability (PI David Bates)
£159,208 – over 3 years.
 BHF Project Grant. VEGF165b function in vivo. £173647. Aug-2008-2011 (PI-Dave Bates)
2007
 Phase I Development award Philogene. Inc £125,000 (PI): currently negotiating 2008 support.
 Cancer Research UK Project grant. Alternative splice forms of VEGF in colorectal cancer. £163,484. Oct
2007-Oct 2010 (PI David Bates)
 NBHT Research Foundation 12 mths. Towards an AMD treatment £ 49,985 (PI)
 AICR project grant. Alternative splice forms of VEGF in cancer – possible value in anti-VEGF therapy.
£150,000. Oct 2007-Oct 2010 (PI David Bates)
 MRC project grant. Regulation of glomerular permeability. £335,189. 1.Jan.07-1.Jan.10 (PI Dave Bates)
 Richard Bright VEGF Research Trust. VEGF165b in Cancer £38,740 (PI)
2006
 Prostate Cancer Research Foundation (PI) - £82,000. 2006-2008. VEGF splicing change as a therapeutic
option in Prostate Cancer.
 Kidney Research UK start up grant. Anti-proteinuric effect of Angiopoietin-1 on human glomeruli. £30,000.
Sep 2006-August 2007. Principal applicant. Andrew Salmon
 Fight for Sight project grant. Inhibition of retinal neovascularisation by inhibitory VEGF splice variants .
£140,000. Sep 2006-Aug 2009.(PI Dave Bates)
 Wellcome Trust Project Grant. VEGF in choroidal neovascularisation. £207,466. June 2006-09.(PI Dave
Bates)
 National Eye Research Centre £49,004 2006-7 (PI Amanda Churchill)
2005





2004



British Heart Foundation Post-graduate Studentship. £75,351. 2005-2008. Regulation of novel VEGF
isoforms of VEGF. PI - Dave Bates
British Heart Foundation Post-graduate Studentship. £78881. 2006-2009. Capillary permeability and
ultrastructure in microalbuminuria (PI).
Royal College of Surgeons Fellowship. £50,000. 2005-2006. VEGF165b in colorectal cancer. Co-Sponsor for
Alex Varey.
Cancer Research UK Clinicians Training Bursary. VEGF165b in colorectal cancer. £23,500. 2005. Sponsor
for Alex Varey.
UBHT Specific Cancer Projects Fund. 2005-2006 £37,652. An ultra-structural analysis of tumour
microvessels.(PI)
Prostate Research Campaign. £30,498. 2004-2005. The role of the novel inhibitory VEGF isoform
(VEGF165b) in the treatment of prostate cancer (PI).
Edwin Luff Cancer Fund Project. £67,254. 2004-2006. The role of the anti-angiogenic VEGF isoform
VEGF165b in human cancer (PI).
Wellcome Trust Project Grant. £118, 177. 2004-2006. The Role of Conventional and Novel forms of VEGF
in Lung Injury and Repair. PI - Ann Millar.